Active Filter(s):
Details:
Topical reformulation of oral medication Vioxx (rofecoxib), a COX-2 specific NSAID, aims to alleviate osteoarthritis-related pain of knee and joints in U.S. alone without opioids or adverse side effects due to systemic exposure associated with oral NSAID dosing.
Lead Product(s): Rofecoxib
Therapeutic Area: Musculoskeletal Product Name: Vioxx
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 02, 2022
Details:
Patent covers a reformulation of Vioxx (rofecoxib) called RelῩva, a COX-2 specific NSAID, from an oral to topical formulation with the intention of alleviating osteoarthritis-related pain of knee and joint pain, and reducing need for opioids in certain patient populations.
Lead Product(s): Rofecoxib
Therapeutic Area: Musculoskeletal Product Name: RelYva
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 09, 2022
Details:
The patent covers a reformulation of COX-2 specific NSAID, RelῩva (rofecoxib), to provide those suffering from osteoarthritis a long-lasting non-opioid option for pain relief and reducing the need for opioids in certain patient populations.
Lead Product(s): Rofecoxib
Therapeutic Area: Musculoskeletal Product Name: Relÿva
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 15, 2022